{
  "retracted": false,
  "timestamp": 1420502400000,
  "updates": [
    {
      "timestamp": 1586526917508,
      "identifier": {
        "doi": "10.1212/01.wnl.0000459892.11490.a1"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1212/wnl.0000000000000926"
  },
  "publisher": "Ovid Technologies (Wolters Kluwer Health)",
  "title": "CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS"
}
